📊 PODD Key Takeaways
Is Insulet Corp. (PODD) a Good Investment?
Insulet demonstrates strong fundamentals with exceptional revenue growth of 30.7% YoY and healthy gross margins of 69.5%, indicating solid market positioning in medical devices. However, a concerning 40.9% decline in net income despite robust top-line expansion suggests significant margin compression requiring investigation into underlying drivers—potentially one-time charges, investment spending, or cost pressures.
Insulet Corp. Key Strengths (PODD)
- Exceptional revenue growth of 30.7% YoY reaching $761.7M demonstrates strong market demand
- Excellent gross margin of 69.5% indicates pricing power and operational efficiency
- Positive free cash flow generation of $89.5M (11.8% FCF margin) shows cash conversion ability
- Strong liquidity position with current ratio of 2.49x and quick ratio of 1.81x
- Solid interest coverage ratio of 11.4x demonstrates capacity to service debt obligations
PODD Stock Risks: Insulet Corp. Investment Risks
- Net income declined 40.9% YoY despite 30.7% revenue growth—significant profitability deterioration requires explanation
- Low return metrics (ROE 7.0%, ROA 3.0%) suggest suboptimal capital deployment efficiency
- Substantial long-term debt of $929.5M creates financial leverage risk despite manageable debt-to-equity ratio
- Compressed net margin of 12.0% is low for the medical device sector relative to growth rate
- Elevated insider activity with 22 Form 4 filings in 90 days could indicate executive uncertainty
Key Metrics to Watch
- Net income trend reversal and reconciliation of revenue growth versus earnings decline
- Operating margin sustainability and cost structure evolution
- Free cash flow generation and capital allocation decisions
- Debt reduction progress and refinancing activity
Insulet Corp. (PODD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.49x current ratio provides a solid financial cushion.
PODD Profit Margin, ROE & Profitability Analysis
PODD vs Healthcare Sector: How Insulet Corp. Compares
How Insulet Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Insulet Corp. Stock Overvalued? PODD Valuation Analysis 2026
Based on fundamental analysis, Insulet Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Insulet Corp. Balance Sheet: PODD Debt, Cash & Liquidity
PODD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Insulet Corp.'s revenue has grown significantly by 87% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.94 reflects profitable operations.
PODD Revenue Growth, EPS Growth & YoY Performance
PODD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $569.0M | $35.4M | $0.50 |
| Q3 2025 | $543.9M | $77.5M | $1.08 |
| Q2 2025 | $488.5M | $22.5M | $0.32 |
| Q1 2025 | $441.7M | $35.4M | $0.50 |
| Q3 2024 | $432.7M | $51.9M | $0.74 |
| Q2 2024 | $396.5M | $27.3M | $0.39 |
| Q1 2024 | $358.1M | $23.8M | $0.34 |
| Q3 2023 | $340.8M | -$5.2M | $-0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Insulet Corp. Dividends, Buybacks & Capital Allocation
PODD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Insulet Corp. (CIK: 0001145197)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PODD
What is the AI rating for PODD?
Insulet Corp. (PODD) has an AI grade of B with 70% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PODD's key strengths?
Claude: Exceptional revenue growth of 30.7% YoY reaching $761.7M demonstrates strong market demand. Excellent gross margin of 69.5% indicates pricing power and operational efficiency.
What are the risks of investing in PODD?
Claude: Net income declined 40.9% YoY despite 30.7% revenue growth—significant profitability deterioration requires explanation. Low return metrics (ROE 7.0%, ROA 3.0%) suggest suboptimal capital deployment efficiency.
What is PODD's revenue and growth?
Insulet Corp. reported revenue of $761.7M.
Does PODD pay dividends?
Insulet Corp. does not currently pay dividends.
Where can I find PODD SEC filings?
Official SEC filings for Insulet Corp. (CIK: 0001145197) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PODD's EPS?
Insulet Corp. has a diluted EPS of $1.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PODD's fundamental grade?
Based on our AI fundamental analysis in May 2026, Insulet Corp. has a B grade with 70% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PODD stock overvalued or undervalued?
Valuation metrics for PODD: ROE of 7.0% (sector avg: 15%), net margin of 12.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PODD's AI grade for 2026?
Our dual AI analysis gives Insulet Corp. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PODD's free cash flow?
Insulet Corp.'s operating cash flow is $113.8M, with capital expenditures of $24.3M. FCF margin is 11.8%.
How does PODD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 12.0% (avg: 12%), ROE 7.0% (avg: 15%), current ratio 2.49 (avg: 2).